Article
Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β2-agonists: results of the PACMAN cohort.
Pharmacogenomics - 1 Dec 2013
Zuurhout Miranda J L, Vijverberg Susanne J H, Raaijmakers Jan A M, Koenderman Leo, Postma Dirkje S, Koppelman Gerard H, Maitland-van der Zee Anke Hilse
Abstract excerpt
BACKGROUND: Current evidence suggests that asthma patients with the ADRB2 Arg16 genotype have a poorer response to long-acting β2-agonists (LABA), but the results remain inconsistent. AIM: This study assessed the association between Arg16 variants and treatment outcome in children treated with inhaled corticosteroids (ICS) and LABA. MATERIALS & METHODS: ADRB2 Arg16 was genotyped in 597 children (4-12 years of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.